NVSEF - Novartis Q2 Struck By Deferrable Portfolio Elements But Pipeline Continues To Develop
By Guney Kaya
Novartis (NVS) has been a key pick for us during the coronavirus pandemic. Although a quintessential biopharma company, it has one of the safest pipelines with dozens of therapies already in registration phase or phase III. Their strategic shift to being a more value-add and innovation-based pharma company has borne fruit, with many of their recent therapies, such as Cosentyx and Entresto, driving a large portion of their sales. Their dividend is also attractive, yielding 3.68%, which is on the higher side for a growth-based business, lower only than the